MedCity News
5 months agoMedicine
Vertex's CRISPR Gene Therapy Lands Another FDA Nod in a Rare Blood Disease
Vertex Pharmaceuticals and CRISPR Therapeutics' gene therapy, Casgevy, has received FDA approval as a treatment for beta thalassemia.
The therapy provides a one-time treatment option for transfusion-dependent beta thalassemia patients age 12 and older. [ more ]